Forbion, a venture capital firm, and Jeito Capital, an investment company, led a $112m Series B in Noema Pharma, a clinical-stage biotech company, with participation from UPMC Enterprises, Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus. "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months," Luigi Costa, Noema Pharma CEO.